Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.

  title={Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.},
  author={Ruchika Gutt and Nathan Tonlaar and Rangesh Kunnavakkam and Theodore G. Karrison and Ralph R. Weichselbaum and Stanley L. Liauw},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={28 16},
  • R. GuttN. Tonlaar S. Liauw
  • Published 1 June 2010
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE There has been growing interest in the potential anticancer activity of statins based on preclinical evidence of their antiproliferative, proapoptotic, and radiosensitizing properties. The primary objective of this study was to determine whether statin use is associated with improved clinical outcomes in patients treated with radiotherapy (RT) for prostate cancer. PATIENTS AND METHODS In total, 691 men with prostate adenocarcinoma treated with curative-intent RT between 1988 and 2006… 

Figures and Tables from this paper

Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy.

Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?

Although statin and ASA use were significantly associated with improved prostate cancer specific survival (PCSS) on univariate analysis, neither were on multivariate analysis.

Clinical Potential of Statins in Prostate Cancer Radiation Therapy.

Evidence of statin use in prostate cancer presents many obstacles yet to be overcome, which warrant attention prior to the routine implementation of statins in treatment regimes, however, there is evidence to support their beneficial use.

The association of statin use and biochemical recurrence after curative treatment for prostate cancer

Investigating the association between statin use and biochemical recurrence (BCR) in patients undergoing radical prostatectomy or radiotherapy as a curative treatment foundStatin use is associated with a potential tendency to improve BCR-free survival in prostate cancer and could reduce BCR in high-risk patients.

Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy

In PC patients undergoing RP, statin use was not independently associated with lower risk of BCR, after adjusting for the effects of standard clinicopathologic features.

Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy.

AC therapy, particularly aspirin, was associated with a reduced risk of PCSM in men treated with RT or RP for prostate cancer, and the association was most prominent in patients with high-risk disease.

Targeting Tumor Metabolism With Statins During Treatment for Advanced-stage Pancreatic Cancer

Investigation of the efficacy of statin use as a supplementary treatment option in advanced-stage pancreatic adenocarcinoma patients found it correlated with improved overall survival in this cohort, which supports previous findings in early-stage pancreas cancer and other cancer sites.

Statin use and the risk of prostate-specific antigen recurrence after radiation therapy with or without hormone therapy for prostate cancer.

  • A. D'Amico
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
An interesting hypothesis regarding statin use and a possible decrease in the risk of PSA recurrence in men undergoing RT that requires prospective validation given the retrospective nature of the study as well as alternative explanations for the findings are raised.



Biochemical Control and Toxicity after Intensity-Modulated Radiation Therapy for Prostate Cancer

Patients treated with IMRT for prostate cancer have excellent rates of biochemical control and low rates of severe toxicity of treatment, according to a single-institutional experience in outcomes analysis.

Statin drugs and risk of advanced prostate cancer.

In this cohort of male health professionals, use of statin drugs was not associated with risk of prostate cancer overall but was associated with a reduced risk of advanced (especially metastatic or fatal) prostate cancer.

Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.

Review of major adverse effects of androgen‐deprivation therapy in men with prostate cancer

ADT was associated with an increased risk of skeletal fracture, incident diabetes, and cardiovascular‐related mortality, although the absolute risk of these events was low.

Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era.

Data provide evidence to propose the hypothesis that a short posttreatment PSA DT may serve as a possible surrogate for PCSD, and the cause of death for patients with a short PSADT following RT was nearly always prostate cancer.

The influence of statin medications on prostate-specific antigen levels.

By lowering PSA levels, statins may complicate cancer detection, although further studies are needed to quantify the clinical significance of this effect.

Metabolic and cardiovascular effects of androgen deprivation therapy

There is a need for prospective studies aimed and designed to investigate the metabolic and cardiovascular adverse effects of ADT, and assess the benefit/risk ratio, especially in special populations such as diabetics.